MarketPulse

MASH

11 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Zealand Pharma

Boehringer's Obesity Drug Survodutide Posts Strong Phase 3 Results, Boosting Zealand Pharma

Boehringer's survodutide shows 16.6% weight loss in Phase 3 trial, benefiting Zealand Pharma with EUR 315M in potential milestone payments and ongoing royalties.
ZLDPYPhase 3 trialweight loss
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Boehringer Ingelheim's Dual-Action Obesity Drug Survodutide Shows 16.6% Weight Loss

Boehringer Ingelheim's survodutide achieved 16.6% average weight loss in Phase III trials, with 85.1% of patients hitting ≥5% reduction targets, supporting obesity and MASH treatment potential.
ZLDPYclinical trial resultsweight loss
BenzingaBenzinga··Altimmune Inc

Altimmune Raises $225M in Oversubscribed Offering to Fuel Phase 3 MASH Trial

Altimmune closed a $225M oversubscribed public offering led by Deep Track Capital. Proceeds will fund Phase 3 MASH trial initiation in H2 2026 and operational runway through data readout.
ALTfinancingclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Altimmune Raises $225M in Oversubscribed Offering to Fund MASH Trial

Altimmune raises $225M in oversubscribed offering to fund Phase 3 MASH trial, pricing 64.25M shares at $3.00 each.
ALTwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Madrigal Pharma to Report Q1 2026 Results as Rezdiffra Ramps Up Commercial Launch

Madrigal Pharmaceuticals reports Q1 2026 results May 6, revealing early commercial performance of FDA/EMA-approved MASH treatment Rezdiffra following recent regulatory clearances.
MDGLfinancial resultsFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Proqr Therapeutics N.V.

ProQR Expands Pipeline With Multiple Clinical Catalysts Lined Up Through 2027

ProQR Therapeutics expands pipeline with lead program AX-0810 targeting H1 2026 data readout in biliary atresia, supported by three additional programs advancing through 2027.
LLYPRQRDNAHurler syndromeclinical pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Sagimet Biosciences Unveils MASH Trial Data, Secures Nasdaq Approval for Employee Equity Grant

Sagimet presented Phase 2b denifanstat data showing bile acid biomarker potential in MASH patients, while securing Nasdaq approval for employee stock options.
SGMTclinical trial dataMASH
BenzingaBenzinga··Prnewswire

Galmed Files 2025 Annual Report as Aramchol Advances Through Clinical Pipeline

Galmed files 2025 annual report detailing Aramchol development for NASH and cardiometabolic diseases, including clinical trial progress and regulatory disclosures.
GLMDFDA approvalclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva to Report 2025 Results as MASH Drug Candidate Advances in Phase 3

Inventiva to release 2025 financial results March 30, 2026, as its lanifibranor MASH drug advances through Phase 3 clinical trials.
IVAPhase 3 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Proqr Therapeutics N.V.

ProQR Advances Gene Therapy Pipeline as Cash Runway Extends to Mid-2027

ProQR reported €92.4M cash, advanced lead program AX-0810 into Phase 1, and achieved $4.5M in Eli Lilly milestones, projecting runway into mid-2027.
LLYPRQRPhase 1 clinical trialbiotech pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Gyre Therapeutics Posts 10% Revenue Growth but Guides Lower Amid Strategic Pivot

Gyre Therapeutics posts 10% FY2025 revenue growth to $116.6M, guides 2026 lower due to regulatory prioritization and Cullgen acquisition for TPD expansion.
GYRErevenue guidanceclinical trial